An evaluation of the utility of computed tomography in high-risk endometrial cancer surveillance.

OBJECTIVES: Endometrial cancer is a collection of heterogeneous histologies and molecular subtypes with different risk profiles. High-risk endometrial cancer surveillance regimens vary amongst providers. The National Comprehensive Cancer Network (NCCN) recommends symptom and exam-based surveillance for all endometrial cancers after remission, regardless of cancer stage and histology. Our objective was to identify the first method of detection of recurrence in high-risk endometrial cancers and examine disease recurrence and treatment patterns. METHODS: A retrospective review of patients diagnosed with high-risk endometrial cancer between November 2013 and February 2020 was conducted at a large academic institution. High-risk endometrial cancers were classified by histology and pathologic stage and were categorized by primary method of detection. RESULTS: Two hundred and twenty-nine patients were identified with high-risk endometrial cancer, 63 (28 %) of whom had a recurrence. Most recurrences were first detected with routine imaging in 31 patients (49.2 %) and symptom surveillance in 24 patients (38.15 %). Regardless of the detection method, most patients underwent systemic treatment. The average survival after recurrence was 2.0 years in the imaging cohort and 1.6 years in the non-imaging surveillance cohort. CONCLUSIONS: The most common site of recurrence in our cohort of high-risk endometrial cancer was in the lung, and most recurrences were identified with asymptomatic imaging. Though there was no statistically significant difference between the survival of those who underwent imaging surveillance vs. standard of care, there was a trend toward survival that deems further exploration with a larger cohort.

A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice.

Osimertinib is a tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR) that is used for first-line therapy in EGFR mutated non-small cell lung cancer (NSCLC) based on the results of the randomized FLAURA trial (ClinicalTrials.gov number NCT02296125). We performed a retrospective analysis of baseline characteristics and clinical outcomes in 56 real-world patients treated with osimertinib. In total, 45% of patients were determined to be FLAURA-eligible and 55% were FLAURA-ineligible based on the published inclusion/exclusion criteria of the aforementioned trial. For clinical outcomes, the median osimertinib time to treatment discontinuation (TTD) for all patients was 16.9 months (95% CI: 12.6-35.1), whereas the median TTD was 31.1 months (95% CI: 14.9-not reached) in the FLAURA-eligible cohort and the median TTD was 12.2 months (95% CI: 8.1-34.6 months) in the FLAURA-ineligible cohort. Re-biopsy at acquired resistance disclosed both on- and off-target mechanisms. The most common therapies following osimertinib included local therapies followed by post-progression osimertinib, platinum-doublet chemotherapy with or without osimertinib, and osimertinib combinatory targeted therapies. The median overall survival for all patients was 32.0 months (95% CI: 15.7-not reached), the median survival was not reached for the FLAURA-eligible cohort, and it was 16.5 months for the FLAURA-ineligible cohort. Our data support the use of osimertinib in real-word settings and highlight the need for designing registration trials that are more inclusive of patient/disease characteristics seen in routine clinical practice. It is yet to be determined if the use of evolving first-line EGFR inhibitor combination strategies (either platinum-doublet chemotherapy plus osimertinib or amivantamab plus lazertinib) will similarly translate from clinical trials to real-word settings.

Oxaliplatin desensitization for ovarian cancer in pregnancy: A case report.

•Incidence of cancer in pregnancy is rising and successful treatment of these patients requires expert multidisciplinary care.•Platinum hypersensitivity reactions in ovarian cancer are commonly treated with desensitization protocols.•To our knowledge, chemotherapy desensitization in pregnant patients has not been previously reported.•Oxaliplatin desensitization during pregnancy may be safe and feasible.

Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer.

Several lines of preclinical evidence indicate that combining PI3K and CDK4/6 inhibitors may further enhance the efficacy of hormonal therapy by overcoming de novo and acquired resistance to PI3K and CDK4/6 blockade. We evaluated the combination of abemaciclib, letrozole and LY3023414 (an orally available, selective inhibitor of the class I PI3K isoforms and mTORC1/2) in recurrent endometrial cancer (EC). This study was terminated prematurely after 5 patients initiated protocol therapy due to discontinuation of further development of LY3023414. We report our findings from these patients, including one with recurrent endometrioid EC with AKT1, CTNNB1 and ESR1 hotspot mutations who had previously progressed through letrozole/everolimus and achieved a partial response to letrozole/abemaciclib/LY3023414.

Non-surgical management of advanced ovarian cancer with maintenance PARP inhibitors.

The standard of care for advanced ovarian cancer is cytoreductive surgery followed by a platinum-taxane combination with PARP inhibition as a maintenance strategy. In practice, many advanced ovarian cancer patients are older and are either not candidates for surgery or decline surgical intervention. There are limited data for using PARP inhibitor maintenance in the non-surgical patient population. We describe two cases of patients with advanced-stage ovarian cancer who received platinum-taxane chemotherapy and declined surgical debulking. They were continued on maintenance PARP inhibitors and have no evidence of disease for over four years.

Storytelling workshop to encourage stakeholder engagement with the Global Initiative for Childhood Cancer.

Storytelling can enhance stakeholder engagement and support the implementation of the World Health Organization and Pan American Health Organization's (PAHO) Global Initiative for Childhood Cancer, which aims to improve care globally for children with cancer. The Initiative aligns with the United Nations Sustainable Development Goals, addressing health, education, inequalities and international collaboration. This report describes the design and implementation of a workshop that used storytelling through film to encourage stakeholders in national cancer control plans to engage with the Initiative in its focal countries in Central America, the Dominican Republic and Haiti. A six-step process was used to develop the virtual workshop hosted by PAHO: (i) define the audience; (ii) define the goals of storytelling; (iii) build an appropriate storyline, including choosing a platform and content, and addressing group dynamics and the length of the film; (iv) guide the workshop's design and implementation with current theoretical frameworks, including the Socioecological Model of Health and the Theory of Change; (v) design interactive group exercises; and (vi) disseminate workshop results. The skills-building component of the day-long workshop included 80 representatives from eight countries in the Region of the Americas, with participants representing pediatric oncology, hospital administration, ministries of health, nonprofit foundations, the scientific community and public health organizations. Outputs from the workshop included (i) a summary report, (ii) an empathy word cloud with live reactions from participants, (iii) qualitative responses (i.e. quotes from participants), (iv) stakeholders' analyses and (v) a prioritization matrix for country-level strategic activities that could be undertaken to strengthen health systems when caring for children with cancer. The workshop used storytelling through film to try to reduce health inequalities and have a regional impact. Combining art, public health and medicine, the workshop created positive change by sharing real-life experiences. Commitment was fostered among stakeholders through their engagement with the workshop, which aimed to increase their awareness of the need and advocacy to improve health systems and enhance access to health care for this vulnerable population.

La narración de historias puede mejorar la participación de las partes interesadas y brindar apoyo para la aplicación de la Iniciativa Mundial contra el Cáncer Infantil de la Organización Mundial de la Salud y la Organización Panamericana de la Salud (OPS), dirigida a mejorar la atención a los pacientes pediátricos con cáncer en todo el mundo. La Iniciativa se enmarca en el contexto de los Objetivos de Desarrollo Sostenible de las Naciones Unidas, que abordan la salud, la educación, las desigualdades y la colaboración internacional. En este informe se describe el diseño y la realización de un taller en el que se utilizó la narración de historias mediante películas para animar a las partes interesadas de los planes nacionales de control del cáncer a colaborar con la iniciativa en los países del proyecto en Centroamérica, Haití y República Dominicana. Para preparar el taller virtual organizado por la OPS, se utilizó un proceso de seis pasos: i) definir el público destinatario; ii) definir los objetivos de la narración; iii) confeccionar una estructura argumental adecuada, incluida la elección del tipo de plataforma y el contenido, y tener en cuenta tanto las dinámicas de grupo como la duración de la película; iv) basar el diseño y la realización del taller en marcos teóricos actuales, incluidos el modelo socioecológico de la salud y la teoría del cambio; v) diseñar ejercicios grupales interactivos; y vi) difundir los resultados del taller. En el componente de adquisición de competencias del taller, de un día de duración, participaron 80 representantes de ocho países de la Región de las Américas, pertenecientes a los ámbitos de la oncología pediátrica, la gestión hospitalaria, los ministerios de salud, fundaciones sin ánimo de lucro, la comunidad científica y organizaciones de salud pública. Los resultados del taller incluyeron i) un resumen del informe, ii) una nube de palabras relacionadas con la empatía que recogía las reacciones en tiempo real de las personas participantes, iii) respuestas cualitativas (es decir, citas de lo expresado por las personas participantes), iv) análisis de las partes interesadas y v) una matriz de priorización de las actividades estratégicas a nivel de país que se podrían llevar a cabo para fortalecer los sistemas de salud a la hora de prestar atención de salud a los pacientes pediátricos con cáncer. En el taller se recurrió a la narración de historias en forma de película para tratar de reducir las inequidades en materia de salud y lograr un impacto a nivel regional. La combinación de arte, salud pública y medicina propició la generación de cambios favorables mediante el intercambio de experiencias de la vida real. Se fomentó el compromiso de las partes interesadas a través de su participación en el taller, lo cual tenía como objetivo aumentar su concientización sobre la importancia de la promoción y la necesidad de mejorar tanto los sistemas de salud como el acceso a la atención de salud para esta población vulnerable.

A narração de histórias pode aumentar o envolvimento das partes interessadas e apoiar a implementação da Iniciativa Global para o Câncer Infantil da Organização Mundial da Saúde e da Organização Pan-Americana da Saúde (OPAS), que visa a melhorar o atendimento a crianças com câncer em âmbito mundial. A Iniciativa está alinhada com os Objetivos de Desenvolvimento Sustentável das Nações Unidas, abordando saúde, educação, desigualdades e colaboração internacional. Este relatório descreve a elaboração e implementação de uma oficina que usou histórias narradas por meio de filmes para incentivar as partes interessadas nos planos nacionais de controle do câncer a se envolverem na Iniciativa em países focais na América Central, além da República Dominicana e do Haiti. Um processo em seis etapas foi usado para desenvolver a oficina virtual organizada pela OPAS: a) definir o público; b) definir os objetivos da narrativa; c) construir um enredo apropriado, com consideração para a escolha de plataforma e do conteúdo, a dinâmica do grupo e a duração do filme; d) orientar a elaboração e implementação da oficina no âmbito de marcos teóricos atuais, como o Modelo Socioecológico de Saúde e a Teoria da Mudança; e) preparar exercícios interativos em grupo; e f) disseminar os resultados da oficina. O componente de desenvolvimento de habilidades da oficina de um dia incluiu 80 representantes de oito países da Região das Américas, com participantes representando oncologia pediátrica, administração hospitalar, ministérios da saúde, fundações sem fins lucrativos, a comunidade científica e organizações de saúde pública. Os resultados da oficina incluíram: a) um relatório resumido; b) uma nuvem de palavras de empatia com reações ao vivo dos participantes; c) respostas qualitativas (ou seja, falas dos participantes); d) análises das partes interessadas; e e) uma matriz de priorização para atividades estratégicas nacionais que poderiam ser realizadas para fortalecer os sistemas de saúde no cuidado de crianças com câncer. A oficina usou histórias narradas por meio de filmes para tentar reduzir as desigualdades de saúde e alcançar um impacto regional. Combinando arte, saúde pública e medicina, a oficina criou uma mudança positiva por meio do compartilhamento de experiências da vida real. A participação na oficina, cujo objetivo era aumentar a conscientização sobre a necessidade de pleitear melhorias nos sistemas de saúde e no acesso à atenção à saúde para essa população vulnerável, fomentou o compromisso entre as partes interessadas.

Storytelling workshop to encourage stakeholder engagement with the Global Initiative for Childhood Cancer

[ABSTRACT]. Storytelling can enhance stakeholder engagement and support the implementation of the World Health Organization and Pan American Health Organization’s (PAHO) Global Initiative for Childhood Cancer, which aims to improve care globally for children with cancer. The Initiative aligns with the United Nations Sustainable Development Goals, addressing health, education, inequalities and international collaboration. This report describes the design and implementation of a workshop that used storytelling through film to encourage stakeholders in national cancer control plans to engage with the Initiative in its focal countries in Central America, the Dominican Republic and Haiti. A six-step process was used to develop the virtual workshop hosted by PAHO: (i) define the audience; (ii) define the goals of storytelling; (iii) build an appropriate storyline, including choosing a platform and content, and addressing group dynamics and the length of the film; (iv) guide the workshop’s design and implementation with current theoretical frameworks, including the Socioecological Model of Health and the Theory of Change; (v) design interactive group exercises; and (vi) disseminate workshop results. The skills-building component of the day-long workshop included 80 representatives from eight countries in the Region of the Americas, with participants representing pediatric oncology, hospital administration, ministries of health, nonprofit foundations, the scientific community and public health organizations. Outputs from the workshop included (i) a summary report, (ii) an empathy word cloud with live reactions from participants, (iii) qualitative responses (i.e. quotes from participants), (iv) stakeholders’ analyses and (v) a prioritization matrix for country-level strategic activities that could be undertaken to strengthen health systems when caring for children with cancer. The workshop used storytelling through film to try to reduce health inequalities and have a regional impact. Combining art, public health and medicine, the workshop created positive change by sharing real-life experiences. Commitment was fostered among stakeholders through their engagement with the workshop, which aimed to increase their awareness of the need and advocacy to improve health systems and enhance access to health care for this vulnerable population.

[RESUMEN]. La narración de historias puede mejorar la participación de las partes interesadas y brindar apoyo para la aplicación de la Iniciativa Mundial contra el Cáncer Infantil de la Organización Mundial de la Salud y la Organización Panamericana de la Salud (OPS), dirigida a mejorar la atención a los pacientes pediátricos con cáncer en todo el mundo. La Iniciativa se enmarca en el contexto de los Objetivos de Desarrollo Sostenible de las Naciones Unidas, que abordan la salud, la educación, las desigualdades y la colaboración internacional. En este informe se describe el diseño y la realización de un taller en el que se utilizó la narración de historias mediante películas para animar a las partes interesadas de los planes nacionales de control del cáncer a colaborar con la iniciativa en los países del proyecto en Centroamérica, Haití y República Dominicana. Para preparar el taller virtual organizado por la OPS, se utilizó un proceso de seis pasos: i) definir el público destinatario; ii) definir los objetivos de la narración; iii) confeccionar una estructura argumental adecuada, incluida la elección del tipo de plataforma y el contenido, y tener en cuenta tanto las dinámicas de grupo como la duración de la película; iv) basar el diseño y la realización del taller en marcos teóricos actuales, incluidos el modelo socioecológico de la salud y la teoría del cambio; v) diseñar ejercicios grupales interactivos; y vi) difundir los resultados del taller. En el componente de adquisición de competencias del taller, de un día de duración, participaron 80 representantes de ocho países de la Región de las Américas, pertenecientes a los ámbitos de la oncología pediátrica, la gestión hospitalaria, los ministerios de salud, fundaciones sin ánimo de lucro, la comunidad científica y organizaciones de salud pública. Los resultados del taller incluyeron i) un resumen del informe, ii) una nube de palabras relacionadas con la empatía que recogía las reacciones en tiempo real de las personas participantes, iii) respuestas cualitativas (es decir, citas de lo expresado por las personas participantes), iv) análisis de las partes interesadas y v) una matriz de priorización de las actividades estratégicas a nivel de país que se podrían llevar a cabo para fortalecer los sistemas de salud a la hora de prestar atención de salud a los pacientes pediátricos con cáncer. En el taller se recurrió a la narración de historias en forma de película para tratar de reducir las inequidades en materia de salud y lograr un impacto a nivel regional. La combinación de arte, salud pública y medicina propició la generación de cambios favorables mediante el intercambio de experiencias de la vida real. Se fomentó el compromiso de las partes interesadas a través de su participación en el taller, lo cual tenía como objetivo aumentar su concientización sobre la importancia de la promoción y la necesidad de mejorar tanto los sistemas de salud como el acceso a la atención de salud para esta población vulnerable.

[RESUMO]. A narração de histórias pode aumentar o envolvimento das partes interessadas e apoiar a implementação da Iniciativa Global para o Câncer Infantil da Organização Mundial da Saúde e da Organização Pan-Americana da Saúde (OPAS), que visa a melhorar o atendimento a crianças com câncer em âmbito mundial. A Iniciativa está alinhada com os Objetivos de Desenvolvimento Sustentável das Nações Unidas, abordando saúde, educação, desigualdades e colaboração internacional. Este relatório descreve a elaboração e implementação de uma oficina que usou histórias narradas por meio de filmes para incentivar as partes interessadas nos planos nacionais de controle do câncer a se envolverem na Iniciativa em países focais na América Central, além da República Dominicana e do Haiti. Um processo em seis etapas foi usado para desenvolver a oficina virtual organizada pela OPAS: a) definir o público; b) definir os objetivos da narrativa; c) construir um enredo apropriado, com consideração para a escolha de plataforma e do conteúdo, a dinâmica do grupo e a duração do filme; d) orientar a elaboração e implementação da oficina no âmbito de marcos teóricos atuais, como o Modelo Socioecológico de Saúde e a Teoria da Mudança; e) preparar exercícios interativos em grupo; e f) disseminar os resultados da oficina. O componente de desenvolvimento de habilidades da oficina de um dia incluiu 80 representantes de oito países da Região das Américas, com participantes representando oncologia pediátrica, administração hospitalar, ministérios da saúde, fundações sem fins lucrativos, a comunidade científica e organizações de saúde pública. Os resultados da oficina incluíram: a) um relatório resumido; b) uma nuvem de palavras de empatia com reações ao vivo dos participantes; c) respostas qualitativas (ou seja, falas dos participantes); d) análises das partes interessadas; e e) uma matriz de priorização para atividades estratégicas nacionais que poderiam ser realizadas para fortalecer os sistemas de saúde no cuidado de crianças com câncer. A oficina usou histórias narradas por meio de filmes para tentar reduzir as desigualdades de saúde e alcançar um impacto regional. Combinando arte, saúde pública e medicina, a oficina criou uma mudança positiva por meio do compartilhamento de experiências da vida real. A participação na oficina, cujo objetivo era aumentar a conscientização sobre a necessidade de pleitear melhorias nos sistemas de saúde e no acesso à atenção à saúde para essa população vulnerável, fomentou o compromisso entre as partes interessadas.

Updated COVID-19 clearance time among patients with cancer in the Delta and Omicron waves.

BACKGROUND: COVID-19 infection delays therapy and in-person evaluation for oncology patients, but clinic clearance criteria are not clearly defined. METHODS: We conducted a retrospective review of oncology patients with COVID-19 at a tertiary care center during the Delta and Omicron waves and compared clearance strategies. RESULTS: Median clearance by two consecutive negative tests was 32.0 days (Interquartile Range [IQR] 22.0-42.5, n = 153) and was prolonged in hematologic malignancy versus solid tumors (35.0 days for hematologic malignancy, 27.5 days for solid tumors, p = 0.01) and in patients receiving B-cell depletion versus other therapies. Median clearance by single negative test was reduced to 23.0 days (IQR 16.0-33.0), with recurrent positive rate 25.4% in hematologic malignancy versus 10.6% in solid tumors (p = 0.02). Clearance by a predefined waiting period required 41 days until an 80% negative rate. CONCLUSIONS: COVID-19 clearance remains prolonged in oncology patients. Single-negative test clearance can balance delays in care with risk of infection in patients with solid tumors.

Targeting thiol isomerase activity with zafirlukast to treat ovarian cancer from the bench to clinic.

Thiol isomerases, including PDI, ERp57, ERp5, and ERp72, play important and distinct roles in cancer progression, cancer cell signaling, and metastasis. We recently discovered that zafirlukast, an FDA-approved medication for asthma, is a pan-thiol isomerase inhibitor. Zafirlukast inhibited the growth of multiple cancer cell lines with an IC50 in the low micromolar range, while also inhibiting cellular thiol isomerase activity, EGFR activation, and downstream phosphorylation of Gab1. Zafirlukast also blocked the procoagulant activity of OVCAR8 cells by inhibiting tissue factor-dependent Factor Xa generation. In an ovarian cancer xenograft model, statistically significant differences in tumor size between control vs treated groups were observed by Day 18. Zafirlukast also significantly reduced the number and size of metastatic tumors found within the lungs of the mock-treated controls. When added to a chemotherapeutic regimen, zafirlukast significantly reduced growth, by 38% compared with the mice receiving only the chemotherapeutic treatment, and by 83% over untreated controls. Finally, we conducted a pilot clinical trial in women with tumor marker-only (CA-125) relapsed ovarian cancer, where the rate of rise of CA-125 was significantly reduced following treatment with zafirlukast, while no severe adverse events were reported. Thiol isomerase inhibition with zafirlukast represents a novel, well-tolerated therapeutic in the treatment of ovarian cancer.

Systematic review of marine environmental DNA metabarcoding studies: toward best practices for data usability and accessibility.

The emerging field of environmental DNA (eDNA) research lacks universal guidelines for ensuring data produced are FAIR-findable, accessible, interoperable, and reusable-despite growing awareness of the importance of such practices. In order to better understand these data usability challenges, we systematically reviewed 60 peer reviewed articles conducting a specific subset of eDNA research: metabarcoding studies in marine environments. For each article, we characterized approximately 90 features across several categories: general article attributes and topics, methodological choices, types of metadata included, and availability and storage of sequence data. Analyzing these characteristics, we identified several barriers to data accessibility, including a lack of common context and vocabulary across the articles, missing metadata, supplementary information limitations, and a concentration of both sample collection and analysis in the United States. While some of these barriers require significant effort to address, we also found many instances where small choices made by authors and journals could have an outsized influence on the discoverability and reusability of data. Promisingly, articles also showed consistency and creativity in data storage choices as well as a strong trend toward open access publishing. Our analysis underscores the need to think critically about data accessibility and usability as marine eDNA metabarcoding studies, and eDNA projects more broadly, continue to proliferate.

Serial Interval and Incubation Period Estimates of Monkeypox Virus Infection in 12 Jurisdictions, United States, May-August 2022.

Using data from 12 US health departments, we estimated mean serial interval for monkeypox virus infection to be 8.5 (95% credible interval 7.3-9.9) days for symptom onset, based on 57 case pairs. Mean estimated incubation period was 5.6 (95% credible interval 4.3-7.8) days for symptom onset, based on 35 case pairs.

Outbreaks of SARS-CoV-2 Infections in Nursing Homes during Periods of Delta and Omicron Predominance, United States, July 2021-March 2022.

SARS-CoV-2 infections among vaccinated nursing home residents increased after the Omicron variant emerged. Data on booster dose effectiveness in this population are limited. During July 2021-March 2022, nursing home outbreaks in 11 US jurisdictions involving >3 infections within 14 days among residents who had received at least the primary COVID-19 vaccine(s) were monitored. Among 2,188 nursing homes, 1,247 outbreaks were reported in the periods of Delta (n = 356, 29%), mixed Delta/Omicron (n = 354, 28%), and Omicron (n = 536, 43%) predominance. During the Omicron-predominant period, the risk for infection within 14 days of an outbreak start was lower among boosted residents than among residents who had received the primary vaccine series alone (risk ratio [RR] 0.25, 95% CI 0.19-0.33). Once infected, boosted residents were at lower risk for all-cause hospitalization (RR 0.48, 95% CI 0.40-0.49) and death (RR 0.45, 95% CI 0.34-0.59) than primary vaccine-only residents.

Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) outbreaks in nursing homes involving residents who had completed a primary coronavirus disease 2019 (COVID-19) vaccine series-13 US jurisdictions, July-November 2021.

Among nursing home outbreaks of coronavirus disease 2019 (COVID-19) with ≥3 breakthrough infections when the predominant severe acute respiratory coronavirus virus 2 (SARS-CoV-2) variant circulating was the SARS-CoV-2 δ (delta) variant, fully vaccinated residents were 28% less likely to be infected than were unvaccinated residents. Once infected, they had approximately half the risk for all-cause hospitalization and all-cause death compared with unvaccinated infected residents.

A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer.

PURPOSE: Estrogen receptor (ER)-positive endometrial cancers (ECs) are characterized by phosphatidylinositol 3-kinase (PI3K) and receptor tyrosine kinase (RTK)/RAS/ß-catenin (CTNNB1) pathway alterations in approximately 90% and 80% of cases, respectively. Extensive cross-talk between ER, PI3K, and RTK/RAS/CTNNB1 pathways leads to both ligand-dependent and ligand-independent ER transcriptional activity as well as upregulation of cyclin D1 which, in complex with cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), is a critical regulator of cell cycle progression and a key mediator of resistance to hormonal therapy. We hypothesized that the combination of the aromatase inhibitor letrozole and CDK4/6 inhibitor abemaciclib would demonstrate promising activity in this setting. METHODS: We conducted a phase II, two-stage study of letrozole/abemaciclib in recurrent ER-positive EC. Eligibility criteria included measurable disease, no limit on prior therapies, and all EC histologies; prior hormonal therapy was allowed. Primary end points were objective response rate by RECIST 1.1 and progression-free survival (PFS) rate at 6 months. RESULTS: At the data cutoff date (December 03, 2021), 30 patients (28 with endometrioid EC) initiated protocol therapy; 15 (50%) patients had prior hormonal therapy. There were nine total responses (eight confirmed), for an objective response rate of 30% (95% CI, 14.7 to 49.4), all in endometrioid adenocarcinomas. Median PFS was 9.1 months, PFS at 6 months was 55.6% (95% CI, 35.1 to 72), and median duration of response was 7.4 months. Most common ≥ grade 3 treatment-related adverse events were neutropenia (20%) and anemia (17%). Responses were observed regardless of grade, prior hormonal therapy, mismatch repair, and progesterone receptor status. Exploratory tumor profiling revealed several mechanistically relevant candidate predictors of response (CTNNB1, KRAS, and CDKN2A mutations) or absence of response (TP53 mutations), which require independent validation. CONCLUSION: Letrozole/abemaciclib demonstrated encouraging and durable evidence of activity in recurrent ER positive endometrioid EC.

Storytelling workshop to encourage stakeholder engagement with the Global Initiative for Childhood Cancer / Taller de narrativa para fomentar la participación de las partes interesadas en la Iniciativa Mundial contra el Cáncer Infantil / Oficina de histórias para incentivar o envolvimento das partes interessadas na Iniciativa Global para o Câncer Infantil

ABSTRACT Storytelling can enhance stakeholder engagement and support the implementation of the World Health Organization and Pan American Health Organization's (PAHO) Global Initiative for Childhood Cancer, which aims to improve care globally for children with cancer. The Initiative aligns with the United Nations Sustainable Development Goals, addressing health, education, inequalities and international collaboration. This report describes the design and implementation of a workshop that used storytelling through film to encourage stakeholders in national cancer control plans to engage with the Initiative in its focal countries in Central America, the Dominican Republic and Haiti. A six-step process was used to develop the virtual workshop hosted by PAHO: (i) define the audience; (ii) define the goals of storytelling; (iii) build an appropriate storyline, including choosing a platform and content, and addressing group dynamics and the length of the film; (iv) guide the workshop's design and implementation with current theoretical frameworks, including the Socioecological Model of Health and the Theory of Change; (v) design interactive group exercises; and (vi) disseminate workshop results. The skills-building component of the day-long workshop included 80 representatives from eight countries in the Region of the Americas, with participants representing pediatric oncology, hospital administration, ministries of health, nonprofit foundations, the scientific community and public health organizations. Outputs from the workshop included (i) a summary report, (ii) an empathy word cloud with live reactions from participants, (iii) qualitative responses (i.e. quotes from participants), (iv) stakeholders' analyses and (v) a prioritization matrix for country-level strategic activities that could be undertaken to strengthen health systems when caring for children with cancer. The workshop used storytelling through film to try to reduce health inequalities and have a regional impact. Combining art, public health and medicine, the workshop created positive change by sharing real-life experiences. Commitment was fostered among stakeholders through their engagement with the workshop, which aimed to increase their awareness of the need and advocacy to improve health systems and enhance access to health care for this vulnerable population.

resumen está disponible en el texto completo

RESUMO A narração de histórias pode aumentar o envolvimento das partes interessadas e apoiar a implementação da Iniciativa Global para o Câncer Infantil da Organização Mundial da Saúde e da Organização Pan-Americana da Saúde (OPAS), que visa a melhorar o atendimento a crianças com câncer em âmbito mundial. A Iniciativa está alinhada com os Objetivos de Desenvolvimento Sustentável das Nações Unidas, abordando saúde, educação, desigualdades e colaboração internacional. Este relatório descreve a elaboração e implementação de uma oficina que usou histórias narradas por meio de filmes para incentivar as partes interessadas nos planos nacionais de controle do câncer a se envolverem na Iniciativa em países focais na América Central, além da República Dominicana e do Haiti. Um processo em seis etapas foi usado para desenvolver a oficina virtual organizada pela OPAS: a) definir o público; b) definir os objetivos da narrativa; c) construir um enredo apropriado, com consideração para a escolha de plataforma e do conteúdo, a dinâmica do grupo e a duração do filme; d) orientar a elaboração e implementação da oficina no âmbito de marcos teóricos atuais, como o Modelo Socioecológico de Saúde e a Teoria da Mudança; e) preparar exercícios interativos em grupo; e f) disseminar os resultados da oficina. O componente de desenvolvimento de habilidades da oficina de um dia incluiu 80 representantes de oito países da Região das Américas, com participantes representando oncologia pediátrica, administração hospitalar, ministérios da saúde, fundações sem fins lucrativos, a comunidade científica e organizações de saúde pública. Os resultados da oficina incluíram: a) um relatório resumido; b) uma nuvem de palavras de empatia com reações ao vivo dos participantes; c) respostas qualitativas (ou seja, falas dos participantes); d) análises das partes interessadas; e e) uma matriz de priorização para atividades estratégicas nacionais que poderiam ser realizadas para fortalecer os sistemas de saúde no cuidado de crianças com câncer. A oficina usou histórias narradas por meio de filmes para tentar reduzir as desigualdades de saúde e alcançar um impacto regional. Combinando arte, saúde pública e medicina, a oficina criou uma mudança positiva por meio do compartilhamento de experiências da vida real. A participação na oficina, cujo objetivo era aumentar a conscientização sobre a necessidade de pleitear melhorias nos sistemas de saúde e no acesso à atenção à saúde para essa população vulnerável, fomentou o compromisso entre as partes interessadas.

Monitoring Endocrine Complications of Immunotherapy: A Screening Tool.

Introduction The advent of immunotherapy has revolutionized cancer therapy in recent years. Immunotherapy using monoclonal antibodies against checkpoint molecules, including programmed death (PD)-1, PD ligand (PD-L)1, and cytotoxic T-lymphocyte antigen 4 (CTLA)-4, has become a cornerstone in cancer therapy. However, due to the physiologic role of checkpoint molecules in preventing autoimmunity, immune-related adverse events (irAEs) have emerged as frequent complications. As the use of immunotherapy increases, a better understanding of irAEs and screening tools for timely diagnosis and management are needed. Materials and methods We surveyed oncology providers at our institution with 10 questions assessing their knowledge, and comfort levels in diagnosing and managing endocrine irAEs. We created an endocrine clinic referral order specifically for oncology-related endocrinopathies and created a screening tool for diagnosing these endocrinopathies. We met with our oncology providers in three different hour-long sessions. A post-intervention survey was sent out six months after our initial meeting to assess changes in the participants' knowledge and comfort levels. We also reviewed the electronic medical records system for the number of new referrals to endocrinology clinic. Results A total of 27 (N) participants responded to the initial survey and 14 (n) responded to the subsequent survey six months later. Based on the initial survey, only a minority (26%) of respondents were comfortable diagnosing and managing (15%) immunotherapy-related adrenal dysfunction whereas more respondents were comfortable diagnosing (55%) and managing (56%) thyroid dysfunction. The majority (67%) of the respondents knew which immunotherapies commonly are implicated in hypophysitis but only 42% of them were aware of the next steps of its management. We noted a significant increase in self-reported comfort levels in diagnosing (p < 0.05) and managing (p < 0.05) adrenal disorders post-intervention. There was also a trend of improvement in participants' comfort levels regarding diagnosing and managing thyroid dysfunction, management of hypophysitis, and immunotherapies implicated in thyroid dysfunction but the changes did not reach statistical significance. There was no significant change in their knowledge regarding immunotherapies implicated in hypophysitis and natural history of thyroid dysfunction in this setting. In the six months following our intervention, 30% (n=21) of the patients referred to the endocrine clinic were for immune-related endocrinopathies compared to 19% (n=7) of patients over a similar duration before the intervention. Data on the time between referral and endocrinology appointment was available for 16 out of the 21 patients and the mean (±SD) time to endocrine clinic appointment was 2.66 (±1.95) weeks. Nine (43%) of the 21 referred patients were seen in endocrinology clinic within two weeks. Conclusions Although immune-related endocrinopathies are rarely fatal, they have a significant impact on patients' quality of life. Endocrinopathies are typically manageable with prompt recognition and treatment. But the subtle and non-specific manifestations make the diagnostic process a challenge. Standardized and practical screening tools can help in diagnosing these adverse events promptly, seeking specialized care if needed and may also aid in reducing healthcare-related costs.

Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer.

Importance: Although the activity of pembrolizumab and lenvatinib (the only US Food and Drug Administration-approved immunotherapy for mismatch repair proficient endometrial cancer [MMRP EC]) is compelling, there are no biomarkers of response and most patients do not tolerate, do not respond to, or develop resistance to this regimen, highlighting the need for additional, potentially biomarker-driven therapeutic approaches for patients with recurrent MMRP EC. Objective: To assess the potential positive outcomes and safety of the combination of the polyadenosine diphosphate-ribose polymerase inhibitor talazoparib and the programmed cell death ligand 1 (PD-L1) inhibitor avelumab in recurrent MMRP EC. Design, Settings, and Participants: This investigator-initiated, open-label, single-arm, 2-stage, phase 2 study nonrandomized controlled trial patients at 4 institutions in the US. Key eligibility criteria included measurable disease, unlimited prior therapies, and all endometrial cancer histologies. Interventions: Talazoparib, 1 mg, orally, daily, and avelumab, 10 mg/kg, intravenously, every 2 weeks, were administered until disease progression or unacceptable toxic effects. Main Outcomes and Measures: Statistical considerations were developed for 2 coprimary objectives of objective response rate and rate of progression-free survival at 6 months, with a 2-stage design that allowed for early discontinuation for futility. Prespecified exploratory objectives included the association of immunogenomic features (determined by targeted-panel next-generation sequencing and immunohistochemistry) with activity. Results: Thirty-five female patients (mean [SD] age, 67.9 [8.41] years) received protocol therapy; 9 (25.7%) derived clinical benefit after meeting at least 1 of the 2 coprimary end points. Four patients (11.4%) exhibited confirmed objective response rates (4 partial responses), and 8 (22.9%) survived progression free at 6 months. The most common grade 3 and 4 treatment-related toxic effects were anemia (16 [46%]), thrombocytopenia (10 [29%]), and neutropenia (4 [11%]); no patient discontinued receipt of therapy because of toxic effects. Tumors with homologous recombination repair alterations were associated with clinical benefit from treatment with avelumab and talazoparib. Tumor mutational burden, tumor-infiltrating lymphocytes, and PD-L1 status were not associated with clinical benefit. Conclusions and Relevance: The results of this nonrandomized controlled trial suggest that treatment with avelumab and talazoparib demonstrated a favorable toxic effect profile and met the predetermined criteria to be considered worthy of further evaluation in MMRP EC. Immunogenomic profiling provided insights that may inform ongoing and future studies of polyadenosine diphosphate-ribose polymerase and PD-L1 inhibitor combinations in endometrial cancer. Trial Registration: ClinicalTrials.gov Identifier: NCT02912572.

Management of recurrent cervical cancer with peritoneal carcinomatosis with HIPEC.

Cervical cancer is the fourth most common malignancy in women in the world; however, a substantial portion of these malignancies are declining with increasingly sophisticated screening. Unfortunately, recurrent cervical cancer has a dismal prognosis and its management continues to be a growing area of research. While the foundation of treatment remains platinum-based chemotherapies, new techniques such as HIPEC have been evaluated. We present two patients with recurrent cervical adenocarcinoma with peritoneal carcinomatosis who were treated with HIPEC during de-bulking surgery with substantial disease-free survival. One of our patients had 15 months of disease-free survival before developing biliary metastases and the other remains disease free for over 24 months.

Heterogeneity in the Returns to Credits for Public Two-Year College Entrants.

Public two-year colleges offer an entry point to postsecondary education for many Americans who might otherwise forgo college. Most students leave college without a credential. A growing body of research examines the returns to higher education among two-year college entrants but primarily focuses on returns to credentials. This study examines the returns to different types of credits, including academic, technical, and developmental credits. In a series of individual fixed effects models, we use state administrative data following a population of public two-year college entrants to understand which college credits yield the greatest returns and how returns to credits vary across degree attainment. Our findings illustrate that average estimates of the returns to credits obscure varied patterns of returns among two-year college students, where sub-baccalaureate credential recipients appear to experience different returns to academic and technical credits compared with their peers.

Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - Mesa County, Colorado, April-June 2021.

On May 5, 2021, the Colorado Department of Public Health and Environment (CDPHE) identified the first five COVID-19 cases caused by the SARS-CoV-2 B.1.617.2 (Delta) variant in Mesa County in western Colorado (population 154,933, <3% of the state population). All five initial cases were associated with school settings. Through early June, Mesa County experienced a marked increase in the proportion of Delta variant cases identified through sequencing: the 7-day proportion of sequenced specimens identified as B.1.617.2 in Mesa County more than doubled, from 43% for the week ending May 1 to 88% for the week ending June 5. As of June 6, more than one half (51%) of sequenced B.1.617.2 specimens in Colorado were from Mesa County. CDPHE assessed data from surveillance, vaccination, laboratory, and hospital sources to describe the preliminary epidemiology of the Delta variant and calculate crude vaccine effectiveness (VE). Vaccination coverage in early May in Mesa County was lower (36% of eligible residents fully vaccinated) than that in the rest of the state (44%). Compared with that in all other Colorado counties, incidence, intensive care unit (ICU) admissions, and COVID-19 case fatality ratios were significantly higher in Mesa County during the analysis period, April 27-June 6, 2021. In addition, during the same time period, the proportion of COVID-19 cases in persons who were fully vaccinated (vaccine breakthrough cases) was significantly higher in Mesa County compared with that in all other Colorado counties. Estimated crude VE against reported symptomatic infection for a 2-week period ending June 5 was 78% (95% confidence interval [CI] = 71%-84%) for Mesa County and 89% (95% CI = 88%-91%) for other Colorado counties. Vaccination is a critical strategy for preventing infection, serious illness, and death from COVID-19. Enhanced mitigation strategies, including masking in indoor settings irrespective of vaccination status, should be considered in areas with substantial or high case rates.